# US 2021/0341498 A1 · Blood-clotting-system analysis apparatus, blood-clotting-system analysis method, and blood-clotting-system analysis program

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341498 A1
- Document ID: US20210341498A1
- Status: Published application
- Kind: A1
- Application number: 17/271,540
- Filed: 2019-09-06
- Published: 2021-11-04
- Earliest claimed: 2018-09-07
- Assignees: Sony Corporation
- Applicants: Sony Corporation
- Inventors: Yoshihito Hayashi; Seunmin Lee; Aya Fuchigami; Kenzo Machida
- Web page: https://patentgrep.com/patent/US20210341498A1

## CPC

- G01N 33/4905: {Determining clotting time of blood (by chemical methods G01N33/86, C12Q1/56)}
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 27/026: {Dielectric impedance spectroscopy (electrochemical impedance spectroscopy for measuring corrosion G01N17/02)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

There is provided a blood-clotting-system analysis apparatus, including: a pair of electrodes; an application unit configured to apply alternating voltage to the pair of electrodes at predetermined time intervals; a measurement unit configured to measure a complex dielectric constant of a blood sample placed between the pair of electrodes; and an analysis unit configured to analyze, by using at least two or more types of blood clotting-related assays, activity of a clotting factor and activity of a clotting inhibition factor on a basis of a complex dielectric constant of a particular frequency in a predetermined time period measured at the time intervals after an anticoagulant effect acting on the blood sample is resolved.

## Claims

### Claim 1

A blood coagulation system analysis device, comprising:
circuitry configured to:
perform a first blood clotting-related assay on a first blood sample;
perform a second blood clotting-related assay on a second blood sample; and
evaluate an activity of a clotting factor and an activity of a clotting inhibition factor based, at least in part, on an output of the first blood clotting-related assay and an output of the second blood clotting-related assay,
wherein the first blood sample and the second blood sample are distributed from a same blood sample collected from a patient.

### Claim 2 (depends on 1)

The blood coagulation system analysis device of claim 1, wherein the circuitry is further configured to output information indicating a thrombosis risk and/or information indicating a bleeding risk for the patient based, at least in part on the output of the first blood clotting-related assay and the output of the second blood clotting-related assay.

### Claim 3 (depends on 1)

The blood coagulation system analysis device of claim 1, wherein the first blood clotting-related assay comprises an extrinsic clotting pathway triggering assay, and the second blood clotting-related assay comprises an intrinsic clotting pathway triggering assay.

### Claim 4 (depends on 3)

The blood coagulation system analysis device of claim 3, wherein the extrinsic clotting pathway triggering assay comprises an extrinsic weak triggering assay and/or the intrinsic clotting pathway triggering assay comprises an intrinsic weak triggering assay.

### Claim 5 (depends on 1)

The blood coagulation system analysis device of claim 1, wherein the first and second blood clotting-related assays are selected from the group consisting of an assay that triggers no blood clotting reaction, an intrinsic strong triggering assay, an intrinsic weak triggering assay, an extrinsic strong triggering assay, and an extrinsic weak triggering assay.

### Claim 6 (depends on 1)

The blood coagulation system analysis device of claim 1, wherein the first blood clotting-related assay comprises a strong triggering assay and the second blood clotting-related assay comprises a weak triggering assay.

### Claim 7 (depends on 1)

The blood coagulation system analysis device of claim 1, wherein the output of the first blood clotting-related assay and/or the output of the second blood clotting-related assay comprises a blood clotting time.

### Claim 8 (depends on 1)

The blood coagulation system analysis device of claim 1, wherein
the first blood clotting-related assay comprises an intrinsic weak triggering assay configured to output a first clotting time,
the second blood clotting-related assay comprises an intrinsic strong triggering assay configured to output a second clotting time, and
the circuitry is further configured to perform a third blood clotting-related assay comprising an extrinsic weak triggering assay configured to output a third clotting time.

### Claim 9 (depends on 8)

The blood coagulation system analysis device of claim 8, wherein determining an activity of a clotting factor and an activity of a clotting inhibition factor comprises:
(i) comparing the first clotting time to a first threshold;
(ii) comparing the second clotting time to a second threshold;
(iii) comparing the third clotting time to a third threshold; and
outputting information indicating a thrombosis risk and/or information indicating a bleeding risk for the patient based, at least in part, on one or more of the comparisons (i), (ii), and (iii).

### Claim 10 (depends on 1)

The blood coagulation system analysis device of claim 1, wherein the circuitry is further configured to:
determine a first dielectric constant spectrum based on the output of the first blood clotting-related assay;
extract a value for one or more features from the first dielectric constant spectrum;
determine a second dielectric constant spectrum based on the output of the second blood clotting-related assay;
extract a value for the one or more features from the second dielectric constant spectrum; and
evaluate the activity of a clotting factor and the activity of a clotting inhibition factor based on the value extracted for the one or more features from the first dielectric constant spectrum and the value extracted for the one or more features from the second dielectric constant spectrum.

### Claim 11 (depends on 10)

The blood coagulation system analysis device of claim 10, wherein the one or more features comprises a time CT at which the dielectric constant has a minimum value and a time CT3 at which a slope of the dielectric constant is maximum.

### Claim 12 (depends on 1)

The blood coagulation system analysis device of claim 1, wherein the circuitry is further configured to:
provide as input to a trained model, information associated with the output of the first blood clotting-related assay and information associated with the output of the second blood clotting-related assay, and
wherein the activity of the clotting factor in the blood sample and the activity of the clotting inhibition factor in the blood sample is based, at least in part, on an output of the trained model.

### Claim 13 (depends on 12)

The blood coagulation system analysis device of claim 12, wherein
the information associated with the output of the first blood clotting related assay comprises a value for one or more features extracted from a dielectric constant spectrum determined based on the output of the first blood clotting-related assay, and
the information associated with the output of the second blood clotting-related assay comprises a value for the one or more features extracted from a dielectric constant spectrum determined based on the output of the second blood clotting-related assay.

### Claim 14 (depends on 12)

The blood coagulation system analysis device of claim 12, wherein the trained model comprises a model trained using one or more machine learning techniques.

### Claim 15 (depends on 1)

The blood coagulation system analysis device of claim 1, wherein the circuitry further comprises:
a measurement unit configured to perform the first and second blood clotting-related assays, the measurement unit configured to measure the dielectric impedance of the first and second blood samples, when each is arranged between electrodes to which an alternating voltage is applied.

### Claim 16

A method of analyzing a blood sample to determine an amount of a thrombosis risk and/or an amount of a bleeding risk of a patient associated with the blood sample, the method comprising:
performing a first blood clotting-related assay on a first blood sample;
performing a second blood clotting-related assay on a second blood sample; and
evaluating an activity of a clotting factor and an activity of a clotting inhibition factor based, at least in part, on an output of the first blood clotting-related assay and an output of the second blood clotting-related assay,
wherein the first blood sample and the second blood sample are distributed from a same blood sample collected from a patient.

### Claim 17

A blood coagulation analysis system, comprising:
a first electrode and a second electrode arranged opposite the first electrode such that a container including a first blood sample may be arranged between the first and second electrodes;
a voltage generator configured to apply an alternating voltage to the first electrode and the second electrode; and
circuitry configured to:
perform a first blood clotting-related assay on the first blood sample when the alternating voltage is applied to the first and second electrodes;
perform a second blood clotting-related assay on a second blood sample; and
evaluate an activity of a clotting factor and an activity of a clotting inhibition factor based, at least in part, on an output of the first blood clotting-related assay and an output of the second blood clotting-related assay,
wherein the first blood sample and the second blood sample are distributed from a same blood sample collected from a patient.
